[1] Shi Y, Han Y, Yang J, Liu P, He X, Zhang C, et al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res. 2019;31(1):152-161.doi: 10.21147/j.issn.1000-9604.2019.01.10.
[2] O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys. 1995;33(3):663-673.doi: 10.1016/0360-3016(95)00207-F.
[3] Biccler JL, Savage KJ, Brown PDN, Jørgensen J, Larsen TS, Poulsen CB, et al . Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. Leuk Lymphoma. 2019;60(10):2516-2523.doi: 10.1080/10428194.2019.1594219.
[4] Eloranta S, Brånvall E, Celsing F, Papworth K, Ljungqvist M, Enblad G, et al. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013. Eur J Haematol. 2018 ;100(1):61-68.doi: 10.1111/ejh.12980.
[5] Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017 ;31(4):846-852.doi: 10.1038/leu.2016.334.
[6] Houillier C, Ghesquières H, Chabrot C, Soussain C, Ahle G, Choquet S, et al. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neurooncol. 2017 ;133(2):315-320. doi: 10.1007/s11060-017-2435-7.
[7] Kobayashi H, Yamaguchi S, Motegi H, Kaneko S, Endou S, Onimaru R, et al. Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma. Chemother. 2019 Feb;31(1):35-41. doi: 10.1080/1120009X.2018.1546984.
[8] Chen C, Sun P, Cui J, Yan S, Chen H, Xia Y, et al. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China. Cancer Med. 2019;8(4):1359-1367.doi: 10.1002/cam4.1906.
[9] Sun X, Liu J, Wang Y, Bai X, Chen Y, Qian J, et al. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma. Oncotarget. 2017 ;8(30):49156-49164.doi: 10.18632/oncotarget.17101.
[10] Han X, Ji Y, Ouyang M, Zhu T, Zhou D, et al. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese. Sci Rep. 2017;7(1):17053.doi: 10.1038/s41598-017-17359-1.
[11] Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18(9):1297-1303. doi: 10.1093/neuonc/now033.
[12] Mao C, Chen F, Li Y, Jiang X, Liu S, Guo H, et al. Characteristics and Outcomes of Primary Central Nervous System Lymphoma: A Retrospective Study of 91 Cases in a Chinese Population. World Neurosurg. 2019 ;123:e15-e24.doi: 10.1016/j.wneu.2018.10.034.
[13] Alnahhas I, Jawish M, Alsawas M, Zukas A, Prokop L, Murad MH, Malkin M. Autologous Stem-Cell Transplantation for Primary Central Nervous System Lymphoma: Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2019 ;19(3):e129-e141.doi: 10.1016/j.clml.2018.11.018.
[14] Chamberlain MC. High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma. J Neurooncol. 2016;126(3):545-550.doi: 10.1007/s11060-015-1994-8.
[15] Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, et al. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol. 2013 Oct;115(1):71-77.doi: 10.1007/s11060-013-1196-1.
[16] Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. Ann Oncol. 2019;30(4):621-628.doi: 10.1093/annonc/mdz032.
[17] Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018;132(21):2240-2248.doi: 10.1182/blood-2018-02-835496.
[18] Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121-130.doi: 10.1016/j.ejca.2019.05.024.
[19] Terziev D, Hutter B, Klink B, Stenzinger A, Stögbauer F, Glimm H, et al. Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma. Eur J Haematol. 2018 Jul;101(1):115-118.doi: 10.1111/ejh.13072.
[20] Frutoso M, Mortier E. NK Cell Hyporesponsiveness: More Is Not Always Better. Int J Mol Sci. 2019;20(18):4514.doi: 10.3390/ijms20184514.
[21] Shaffer BC, Le Luduec JB, Park S, Devlin S, Archer A, Davis E, et al. Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML.Blood Adv. 2021;5(7):2003-2011.doi: 10.1182/bloodadvances.2020002701.
[22] Li L, Kolk M, Fernandez-Vina M, et al. Interrogating the impact of KIR ligand mismatch in engraftment following HLA-disparate stem cell transplantation. Bone Marrow Transplant. 2020;55(12):2294-2297. doi: 10.1038/s41409-020-0957-7.
[23] Marra J, Greene J, Hwang J, Du J, Damon L, Martin T, et al.KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia. J Immunol. 2015;194(9):4222-4230.doi: 10.4049/jimmunol.1402124.
[24] Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, et al.Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. J Immunother Cancer. 2019;7(1):70.doi: 10.1186/s40425-019-0538-8.
[25] Forlenza CJ, Boudreau JE, Zheng J, et al. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. J Clin Oncol. 2016 Jul 20;34(21):2443-2451.doi: 10.1200/JCO.2015.64.9558.
[26] Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-5043.doi: 10.1200/JCO.2005.13.524.
[27] Vilches C, Castaño J, Gómez-Lozano N, Estefanía E. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens, 2007, 70(5):415-422. doi: 10.1111/j.1399-0039.2007.00923.x.
[28] Smith LK. HLA typing by direct DNA sequencing. Methods Mol Biol. 2012;882:67-86.doi: 10.1007/978-1-61779-842-9_5.
[29] Robinson J, Halliwell JA, McWilliam H, Lopez R, Marsh SGE.IPD--the Immuno Polymorphism Database.Nucleic Acids Res. 2013;41(Database issue):D1234-D1240. doi: 10.1093/nar/gks1140.
[30] Yuan XG, Huang YR, Yu T, Xu Y, Liang Y, Zhang XH, et al. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases. Ann Hematol. 2020;99(1):93-104.doi: 10.1007/s00277-019-03821-9.
[31] Kim N, Lim DH, Yoon SE, Kim SG, Kim WS. Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma. J Neurooncol. 2022;156(2):307-316.doi: 10.1007/s11060-021-03909-1.
[32] Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Rosée PL, et al.Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510-e523.doi: 10.1016/S2352-3026(17)30174-6.
[33] Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017(1):565-577.doi: 10.1182/asheducation-2017.1.565.
[34] Schorb E, Fox CP, Kasenda B, Linton K,Martinez-Calle N, Calimeri T, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020 ;189(5):879-887.doi: 10.1111/bjh.16451.
[35] Chiesa S, Hohaus S, Falcinelli L, D'Alò F, Martelli MF, Manfrida S, et al. Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy. Ann Hematol. 2020;99(10):2367-2375.doi: 10.1007/s00277-020-04220-1.
[36] Birsen R, Willems L, Pallud J, Blanc E, Burroni B, Legoff M, et al. Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.Haematologica.2018;103(7):e296-e299.doi: 10.3324/haematol.2017.185843.
[37] Renaud L, Bossard JB, Carpentier B, Terriou L, Cambier N, Chanteau G, et al. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).Eur J Haematol. 2021;107(3):370-373.doi: 10.1111/ejh.13667.
[38] Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018;362(6421):1416-1422.doi: 10.1126/science.aas9090.
[39] Chang MC, Cheng HI, Hsu K, Hsu YN, Kao CW, Chang YF, et al.NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia. Front Immunol. 2019;9:3152.doi: 10.3389/fimmu.2018.03152.
[40] Takuya Sekine, David Marin, Kai Cao, Li L, Mehta P, Shaim H, et al. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.Blood. 2016;128(2):297-312.doi: 10.1182/blood-2016-03-706317.
[41] van der Ploeg K, Le Luduec JB, Stevenson PA, Park S, Gooley TA, Petersdorf EW, et al.HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation.Blood Adv. 2020;4(19):4955-4964.doi: 10.1182/bloodadvances.2020002086.
[42 ]Jeanette E Boudreau, Fabio Giglio, Ted A Gooley, et al. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.J Clin Oncol. 2017;35(20):2268-2278.doi: 10.1200/JCO.2016.70.7059.
[43] Wei B, Liu Z, Fan Y, Wang S, Dong C, Rao W, et al.Analysis of Cellular Heterogeneity in Immune Microenvironment of Primary Central Nervous System Lymphoma by Single-Cell Sequencing. Front Oncol. 2021 ;11:683007.doi: 10.3389/fonc.2021.683007.